Amirkhosravi A, Boulaftali Y, Robles-Carrillo L, Meyer T, McKenzie S E, Francis J L, Bergmeier W
Center for Thrombosis Research, Florida Hospital, Winter Park, FL, USA.
J Thromb Haemost. 2014 Dec;12(12):2113-9. doi: 10.1111/jth.12748. Epub 2014 Oct 30.
Platelet activation via the Fcγ receptor IIa (FcγRIIa) is implicated in the pathogenesis of immune complex (IC)-mediated thrombocytopenia and thrombosis (ITT). We previously showed that ICs composed of antigen and antibodies targeting CD40 ligand (CD40L) or β2 Glycoprotein I (β2GPI) induce ITT in mice transgenic for human FcγRIIa (hFcR) but not wild-type controls (which lack FcγRIIa). Here we evaluated the contribution of the guanine nucleotide exchange factor, CalDAG-GEFI, and P2Y12, key regulators of Rap1 signaling in platelets, to ITT induced by these clinically relevant ICs.
Pre-formed anti-CD40L or anti-β2GPI ICs were injected into hFcR/Caldaggef1(+/+) or hFcR/Caldaggef1(-/-) mice, with or without clopidogrel pretreatment. Animals were observed for symptoms of shock for 30 min, during which time core body temperature was monitored. Platelet counts were obtained before and 30 min after IC injection. Lungs were assessed for thrombosis by histology or near-infrared imaging.
Both CD40L and β2GPI ICs rapidly induced severe thrombocytopenia, shock and a reduction in body temperature in hFcR/Caldaggef1(+/+) mice. hFcR/Caldaggef1(-/-) mice were protected from CD40L and β2GPI IC-induced thrombocytopenia and shock, whereas P2Y12 inhibition had only a modest effect on IC-induced ITT. Consistent with these findings, IC-induced integrin activation in vitro and the accumulation of activated platelets in the lungs of IC-challenged mice was strongly dependent on CalDAG-GEFI.
Our studies demonstrate that CalDAG-GEFI plays a critical role in platelet activation, thrombocytopenia and thrombosis induced by clinically relevant ICs in mice. Thus, CalDAG-GEFI may be a promising target for the intervention of IC-associated, FcγRIIa-mediated thrombotic conditions.
通过Fcγ受体IIa(FcγRIIa)激活血小板与免疫复合物(IC)介导的血小板减少症和血栓形成(ITT)的发病机制有关。我们之前表明,由靶向CD40配体(CD40L)或β2糖蛋白I(β2GPI)的抗原和抗体组成的ICs可在转人FcγRIIa(hFcR)基因的小鼠中诱发ITT,但在野生型对照小鼠(缺乏FcγRIIa)中则不会。在此,我们评估了鸟嘌呤核苷酸交换因子CalDAG-GEFI和血小板中Rap1信号的关键调节因子P2Y12对这些临床相关ICs诱导的ITT的作用。
将预先形成的抗CD40L或抗β2GPI ICs注射到hFcR/Caldaggef1(+/+)或hFcR/Caldaggef1(-/-)小鼠体内,部分小鼠进行氯吡格雷预处理。观察动物30分钟的休克症状,在此期间监测核心体温。在注射IC前和注射后30分钟获取血小板计数。通过组织学或近红外成像评估肺部血栓形成情况。
CD40L和β2GPI ICs均能迅速在hFcR/Caldaggef1(+/+)小鼠中诱发严重血小板减少、休克和体温降低。hFcR/Caldaggef1(-/-)小鼠可免受CD40L和β2GPI ICs诱导的血小板减少和休克影响,而抑制P2Y12对ICs诱导的ITT仅有适度作用。与这些发现一致,ICs在体外诱导的整合素激活以及IC攻击小鼠肺部中活化血小板的积累强烈依赖于CalDAG-GEFI。
我们的研究表明,CalDAG-GEFI在临床相关ICs诱导的小鼠血小板激活、血小板减少和血栓形成中起关键作用。因此,CalDAG-GEFI可能是干预IC相关的、FcγRIIa介导的血栓性疾病的一个有前景的靶点。